Chronic Kidney Disease-mineral Bone Disorder and Active Vitamin D Analogs for Treating Severe Hyperparathyroidism in Children Receiving Chronic Peritoneal Dialysis
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: The aims of this study were to assess the clinical and laboratory profiles of chronic kidney disease-mineral bone disorder (CKD-MBD) and to assess the effects of treatment of active vitamin D analogs on severe hyperparathyroidism (SHPT) in pediatric patients on chronic peritoneal dialysis. Methods: This is a retrospective study included 53 patients who had been undergoing dialysis for more than 1 year, between January 2003 and December 2012. Results: Even after treatment with phosphate binders and active vitamin D analogs, the mean±standard deviation of the percentage of time during peritoneal dialysis that the patients’ serum concentrations of phosphorus, corrected total calcium, and parathyroid hormone (PTH) fell within the Kidney Disease Outcomes Quality Initiative recommended ranges was 25.06±17.47%, 53.30±23.03%, and 11.52± 9.51%, respectively. Clinical symptoms or radiological signs of CKD-MBD were observed in 10 patients (18.9%). There were significant differences in percentage of time that the serum intact PTH concentration was outside of the recommended range between patients with and without symptoms or signs of CKD-MBD (below recommended range, 11.74±7.37% vs. 40.77±25.39%, P <0.001; above the recommended range, 63.79±27.86% vs. 37.09±27.76%, P =0.022). Of the 25 patients with SHPT, high-dose alfacalcidol treatment was required in 13 patients that controlled SHPT in 7 of these patients, without marked complications. Conclusion: Despite our efforts to manage CKD-MBD, patients’ met the recommended ranges from relevant guidelines at a low frequency. The treatment of high-dose active vitamin D analogs was required in about half of the patients with SHPT and effective in about half of them.
Abstract
Purpose: The aims of this study were to assess the clinical and laboratory profiles of chronic kidney disease-mineral bone disorder (CKD-MBD) and to assess the effects of treatment of active vitamin D analogs on severe hyperparathyroidism (SHPT) in pediatric patients on chronic peritoneal dialysis. Methods: This is a retrospective study included 53 patients who had been undergoing dialysis for more than 1 year, between January 2003 and December 2012. Results: Even after treatment with phosphate binders and active vitamin D analogs, the mean±standard deviation of the percentage of time during peritoneal dialysis that the patients’ serum concentrations of phosphorus, corrected total calcium, and parathyroid hormone (PTH) fell within the Kidney Disease Outcomes Quality Initiative recommended ranges was 25.06±17.47%, 53.30±23.03%, and 11.52± 9.51%, respectively. Clinical symptoms or radiological signs of CKD-MBD were observed in 10 patients (18.9%). There were significant differences in percentage of time that the serum intact PTH concentration was outside of the recommended range between patients with and without symptoms or signs of CKD-MBD (below recommended range, 11.74±7.37% vs. 40.77±25.39%, P <0.001; above the recommended range, 63.79±27.86% vs. 37.09±27.76%, P =0.022). Of the 25 patients with SHPT, high-dose alfacalcidol treatment was required in 13 patients that controlled SHPT in 7 of these patients, without marked complications. Conclusion: Despite our efforts to manage CKD-MBD, patients’ met the recommended ranges from relevant guidelines at a low frequency. The treatment of high-dose active vitamin D analogs was required in about half of the patients with SHPT and effective in about half of them.
참고문헌 (20)
- Tangri N, "Effect of bone mineral guideline target achievement on mortality in incident dialysis patients: an analysis of the United Kingdom Renal Registry", Am J Kidney Dis, 57, pp.415~421 (2011)
- Tentori F, "Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS)", Am J Kidney Dis, 52, pp.519~530 (2008)
- Palmer SC, "Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis", Jama, 305, pp.1119~1127 (2011)
- "KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD)", Kidney Int Suppl, pp.S1~S130 (2009)
- "K", DOQI clinical practice guidelines for bone metabolism and disease in children with chronic kidney disease, 2005, S1~S122
- Klaus G, "Prevention and treatment of renal osteodystrophy in children on chronic renal failure: European guidelines", Pediatr Nephrol, 21, pp.151~159 (2006)
- Wesseling-Perry K, "Chronic kidney disease: mineral and bone disorder in children", Semin Nephrol, 33, pp.169~179 (2013)
- Fouque D, "Control of mineral metabolism and bone disease in haemodialysis patients: which optimal targets?", Nephrol Dial Transplant, 28, pp.360~367 (2013)
- Shroff RC, "Mineral metabolism and vascular damage in children on dialysis", J Am Soc Nephrol, 18, pp.2996~3003 (2007)
- Frazao JM, "Intermittent doxercalciferol (1alpha-hydroxyvitamin D(2)) therapy for secondary hyperparathyroidism", Am J Kidney Dis, 36, pp.550~561 (2000)
- Messa P, "The OPTIMA study: assessing a new cinacalcet (Sensipar", Mimpara) treatment algorithm for secondary hyperparathyroidism, 2008, pp.3, 36~45
- Borzych D, "The bone and mineral disorder of children undergoing chronic peritoneal dialysis", Kidney Int, 78, pp.1295~1304 (2010)
- Wesseling-Perry K, "Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism", Kidney Int, 79, pp.112~119 (2011)
- Cho HY, "Prevalence of 25(OH) vitamin D insufficiency and deficiency in pediatric patients on chronic dialysis", Perit Dial Int, 33, pp.398~404 (2013)
- Gonzalez EA, "Vitamin D insufficiency and deficiency in chronic kidney disease. A single center observational study", Am J Nephrol, 24, pp.503~510 (2004)
- Groothoff JW, "Severe bone disease and low bone mineral density after juvenile renal failure", Kidney Int, 63, pp.266~275 (2003)
- Duranton F, "Vitamin D treatment and mortality in chronic kidney disease: a systematic review and meta-analysis", Am J Nephrol, 37, pp.239~248 (2013)
- Naves-Diaz M, "Oral active vitamin D is associated with improved survival in hemodialysis patients", Kidney Int, 74, pp.1070~1078 (2008)
- Shinaberger CS, "Ratio of paricalcitol dosage to serum parathyroid hormone level and survival in maintenance hemodialysis patients", Clin J Am Soc Nephrol, 3, pp.1769~1776 (2008)
- Goodman WG, "Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy", Kidney Int, 46, pp.1160~1166 (1994)